Steps taken after granting the Marketing Authorisation 
For procedures finalised after 1 October 2003 please refer to module 8B. 
Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: 
Scope 
Application 
number 
Type of 
modification1 
Change in or addition of manufacturing site(s) for part or all of the 
manufacturing process 
Change in supplier of an intermediate compound used in the 
manufacture of the active substance 
Minor change of manufacturing process of the active substance 
Change in specification of starting material or intermediate used in 
the manufacture of the active substance 
Change in pack size for a medicinal product 
Change in or addition of manufacturer(s) of active substance. 
Change  in  supplier  of  an  intermediate  compound  used  in 
manufacture of the active substance. 
Minor change of manufacturing process of the active substance. 
Change in test procedure of active substance. 
I/0001 
I/0002 
I/0003 
I/0004 
Change in pack size for a medicinal product 
I/0005 
Update of section 5.1 of the Summary of Product Characteristics  
II/0006 
Change  of  legal  status  with  the  consequent  change  in  section  4.2 
of the Summary of Product Characteristics 
II/0007 
Additional manufacturing site for batch release 
Change in or addition of manufacturer(s) of active substance 
Minor change of manufacturing process of the active substance 
Change in test procedure of active substance 
Increase of the maximum daily dose of pioglitazone to 45 mg 
Extension of indication for the use of pioglitazone as second line 
monotherapy 
Additional strength: tablets of 45 mg 
I/0008 
I/0009 
II/0010 
II/0011 
X/0012 
I 
I 
I 
I 
I 
II 
II 
I 
I 
II 
II 
X 
Notification/ 
Opinion 
issued on2 
15.11.00 
Commission 
Decision 
Issued/amended 
on 
- 
04.12.00 
- 
12.12.00 
16.02.01 
06.04.01 
- 
29.10.01 
19.02.02 
13.12.01 
12.04.02 
21.11.02 
17.03.03 
28.10.02 
26.11.02 
11.12.02 
- 
22.05.03 
28.08.03 
22.05.03 
28.08.03 
26.06.03 
16.09.03 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a 
minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor 
variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II 
application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 
of 7 November 1996.  
N refers to a notification in accordance with Article 61(3) of Directive 2001/83/EC of 6 November 2001. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification 
date. The Commission Decision will be amended accordingly. 
1/1 
ï£©EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                            
 
 
